Organon & Co (OGN)
18.07
-0.71
(-3.78%)
USD |
NYSE |
Nov 01, 16:00
18.02
-0.05
(-0.28%)
After-Hours: 20:00
Organon Net Income (Quarterly): 359.00M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 359.00M |
June 30, 2024 | 195.00M |
March 31, 2024 | 201.00M |
December 31, 2023 | 546.00M |
September 30, 2023 | 58.00M |
June 30, 2023 | 242.00M |
March 31, 2023 | 177.00M |
December 31, 2022 | 108.00M |
September 30, 2022 | 227.00M |
June 30, 2022 | 234.00M |
Date | Value |
---|---|
March 31, 2022 | 348.00M |
December 31, 2021 | 202.00M |
September 30, 2021 | 323.00M |
June 30, 2021 | 427.00M |
March 31, 2021 | 399.00M |
December 31, 2020 | 368.00M |
September 30, 2020 | 547.00M |
June 30, 2020 | 542.00M |
March 31, 2020 | 703.00M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
58.00M
Minimum
Sep 2023
703.00M
Maximum
Mar 2020
326.63M
Average
323.00M
Median
Sep 2021
Net Income (Quarterly) Benchmarks
Eli Lilly and Co | 970.30M |
Biomarin Pharmaceutical Inc | 106.08M |
Cassava Sciences Inc | 6.155M |
Ligand Pharmaceuticals Inc | -51.91M |
TG Therapeutics Inc | 6.879M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 1.582B |
Total Expenses (Quarterly) | 1.192B |
EPS Diluted (Quarterly) | 1.38 |
Enterprise Value | 12.64B |
Gross Profit Margin (Quarterly) | 58.34% |
Profit Margin (Quarterly) | 22.69% |
Earnings Yield | 27.89% |
Operating Earnings Yield | 32.18% |
Normalized Earnings Yield | 31.18 |